首頁 > 市場調查報告書 > 製藥

消化器

全球盲環症候群市場研究報告 - 2023年至2030年的行業分析、規模、佔有率、成長、趨勢和預測

市場調查報告書

商品編碼

1314703

全球盲環症候群市場研究報告 - 2023年至2030年的行業分析、規模、佔有率、成長、趨勢和預測

Global Blind Loop Syndrome Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年07月01日 | 出版商:

Value Market Research | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球盲環症候群市場需求預計將從2022年的 122 億美元增至2030年的近 295.7 億美元，2023-2030年研究期間年複合成長率為 11.7%。

盲環症候群，也稱為停滯環症候群或停滯症候群，是一種影響小腸的疾病。當消化內容物透過小腸部分的正常流動出現異常時，就會發生這種情況，導致細菌過度生長和消化受損。

市場動態：

隨著越來越多的人意識到這種情況並尋求醫療幫助，對治療的需求也在增加。儘管盲環症候群相對罕見，但胃腸道疾病患病率的上升和診斷技術的改進有助於其識別和後續治療。改進的診斷工具（例如成像技術、細菌培養分析和呼氣測試）有助於更準確地識別盲環症候群。這些進步推動了對治療方案的需求，因為患者可以獲得確診並尋求適當的治療。有效治療方法的可用性影響著治療市場。治療通常包括結合使用抗生素來控制細菌過度生長，補充營養以解決吸收不良問題，以及在嚴重情況下進行手術干涉。開發提供更好結果和更少副作用的新藥物或治療方式可以推動市場發展。包括盲環綜合症在內的胃腸道疾病領域進行的研究和開發工作有助於治療市場的成長。這包括探索新的治療標靶、創新的藥物輸送系統和替代治療方案。由於相關症狀和營養缺乏，這種症候群可能會嚴重影響患者的生活品質。因此，對於緩解症狀、改善營養吸收和增強整體健康的治療有著強烈的需求。適當的醫療基礎設施（包括專門從事胃腸病學的醫療專業人員）的可用性在治療市場中發揮著非常重要的作用。此外，有利的保險給付政策和診斷測試、藥物和外科手術的保險範圍可以推動對治療方案的需求。

本研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具還對全球盲環症候群市場的每個細分市場進行了包容性評估。盲環症候群行業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲盲環症候群市場當前和未來的需求。此外，本報告重點關注所有主要地區各個應用領域的需求、估計和預測。

本研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。盲環症候群市場的主要參與者包括Pfizer Inc., Zydus Cadila, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Hitech, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc., Lupin Limited, MerLion Pharmaceuticals GmbH, Sanofi Corporation, Bayer AG, Abbott Laboratories, Allergan, Inc., Novartis AG, Mylan N.V, Melinta Therapeutics, INC., Amneal Pharmaceuticals LLC, LG Chem, Akron Incorporated, Bausch Health, KYORIN Holdings, Inc., Wockhardt。本節包含競爭格局的整體視圖，包括各種戰略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史和預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家/地區銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史和預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家/地區銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史和預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史和預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家/地區銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史和預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第9章：盲環症候群公司的競爭格局

盲環症候群市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第10章：公司簡介

公司股份分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Zydus Cadila

公司簡介
公司收入
產品
最近的發展

Merck & Co. Inc.

公司簡介
公司收入
產品
最近的發展

F. Hoffmann-La Roche Ltd

公司簡介
公司收入
產品
最近的發展

Hitech

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd

公司簡介
公司收入
產品
最近的發展

Johnson & Johnson Services Inc.

公司簡介
公司收入
產品
最近的發展

Lupin Limited

公司簡介
公司收入
產品
最近的發展

MerLion Pharmaceuticals GmbH

公司簡介
公司收入
產品
最近的發展

Sanofi Corporation

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Abbott Laboratories

公司簡介
公司收入
產品
最近的發展

Allergan Inc.

公司簡介
公司收入
產品
最近的發展

Novartis AG

公司簡介
公司收入
產品
最近的發展

Mylan NV

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私營公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR112111664

The global demand for Blind Loop Syndrome Market is presumed to reach the market size of nearly USD 29.57 BN by 2030 from USD 12.2 BN in 2022 with a CAGR of 11.7% under the study period 2023 - 2030.

Blind loop syndrome, also known as stagnant loop syndrome or stasis syndrome, is a medical condition that affects the small intestine. It occurs when there is an abnormality in the normal flow of digestive contents through a portion of the small intestine, resulting in bacterial overgrowth and impaired digestion.

MARKET DYNAMICS:

As more people become aware of the condition and seek medical help, the demand for treatments increases. Although Blind loop syndrome is relatively rare, the rising prevalence of gastrointestinal disorders and improved diagnostic techniques contribute to its identification and subsequent treatment. Improved diagnostic tools such as imaging techniques, bacterial culture analysis, and breath tests help identify Blind loop syndrome more accurately. These advancements drive the demand for treatment options, as patients can receive a confirmed diagnosis and pursue appropriate therapies. The availability of effective therapeutic approaches influences the treatment market. Management typically involves a combination of antibiotics to control bacterial overgrowth, nutritional supplementation to address malabsorption, and surgical intervention in severe cases. The development of novel drugs or treatment modalities that offer better outcomes and fewer side effects can drive the market. Ongoing research and development efforts in the field of gastrointestinal disorders, including Blind loop syndrome, contribute to the growth of the treatment market. This includes the exploration of new therapeutic targets, innovative drug delivery systems, and alternative treatment options. This syndrome can impact significantly on a patient's quality of life due to the associated symptoms and nutrient deficiencies. Therefore, there is a strong demand for treatments that alleviate symptoms, improve nutrient absorption, and enhance overall well-being. The availability of proper healthcare infrastructure, including medical professionals specializing in gastroenterology, plays a vital role in the treatment market. Additionally, favourable reimbursement policies and insurance coverage for diagnostic tests, medications, and surgical procedures can drive the demand for treatment options.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of blind loop syndrome. The growth and trends of blind loop syndrome industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the blind loop syndrome market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Tetracycline
Chlortetracycline
Oxytetracycline
Chloramphenicol

By Route Of Administration

Injectable
Oral
Parenteral

By End-Users

Hospitals
Homecare
Specialty Clinics
Oncologist
Immunologist

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Blind Loop Syndrome market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Blind Loop Syndrome market include Pfizer Inc., Zydus Cadila, Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Hitech, Teva Pharmaceutical Industries Ltd, Johnson & Johnson Services, Inc., Lupin Limited, MerLion Pharmaceuticals GmbH, Sanofi Corporation, Bayer AG, Abbott Laboratories, Allergan, Inc., Novartis AG, Mylan N.V, Melinta Therapeutics, INC., Amneal Pharmaceuticals LLC, LG Chem, Akron Incorporated, Bausch Health, KYORIN Holdings, Inc., and Wockhardt. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . BLIND LOOP SYNDROME - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Route Of Administration
- 3.7.3 Market Attractiveness Analysis By End-Users
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL BLIND LOOP SYNDROME MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Tetracycline Historic and Forecast Sales by Regions
5.5 Chlortetracycline Historic and Forecast Sales by Regions
5.6 Oxytetracycline Historic and Forecast Sales by Regions
5.7 Chloramphenicol Historic and Forecast Sales by Regions

6 . GLOBAL BLIND LOOP SYNDROME MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

6.1 Overview by Route Of Administration
6.2 Historical and Forecast Data
6.3 Analysis by Route Of Administration
6.4 Injectable Historic and Forecast Sales by Regions
6.5 Oral Historic and Forecast Sales by Regions
6.6 Parenteral Historic and Forecast Sales by Regions

7 . GLOBAL BLIND LOOP SYNDROME MARKET ANALYSIS BY END-USERS

7.1 Overview by End-Users
7.2 Historical and Forecast Data
7.3 Analysis by End-Users
7.4 Hospitals Historic and Forecast Sales by Regions
7.5 Homecare Historic and Forecast Sales by Regions
7.6 Specialty Clinics Historic and Forecast Sales by Regions
7.7 Oncologist Historic and Forecast Sales by Regions
7.8 Immunologist Historic and Forecast Sales by Regions

8 . GLOBAL BLIND LOOP SYNDROME MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE BLIND LOOP SYNDROME COMPANIES

9.1. Blind Loop Syndrome Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF BLIND LOOP SYNDROME INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Pfizer Inc.
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Zydus Cadila
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Merck & Co. Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. F. Hoffmann-La Roche Ltd
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Hitech
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Teva Pharmaceutical Industries Ltd
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Johnson & Johnson Services Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Lupin Limited
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. MerLion Pharmaceuticals GmbH
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Sanofi Corporation
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Bayer AG
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. Abbott Laboratories
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
10.15. Allergan Inc.
- 10.15.1. Company Overview
- 10.15.2. Company Revenue
- 10.15.3. Products
- 10.15.4. Recent Developments
10.16. Novartis AG
- 10.16.1. Company Overview
- 10.16.2. Company Revenue
- 10.16.3. Products
- 10.16.4. Recent Developments
10.17. Mylan N.V
- 10.17.1. Company Overview
- 10.17.2. Company Revenue
- 10.17.3. Products
- 10.17.4. Recent Developments